Increased concentrations of genotype-interpreted Ca 19-9 in urine of bladder cancer patients mark diffuse atypia of the urothelium

Abstract We investigated the use of genotype-interpreted measurements of the tumor marker Ca 19-9 in the urine of bladder cancer patients as a marker of the extent of urothelial disease. Ca 19-9 in urine (sialyl-Lea/creatinine ratio) was measured in 81 bladder cancer patients and correlated to T-category, histologic grade, and presence of urothelial dysplasia. As reference group, Ca 19-9 ratio was measured in urine from 21 apparently healthy individuals. The amount of sialyl-Lea expressed is influenced by the Lewis genotype and secretor status. Accordingly, secretor status was determined in urine by a novel ELISA method, and the Lewis genotypes of all of the individuals were determined by PCR cleavage methods. Ca 19-9 concentrations in urine were higher (P <0.01) in bladder cancer patients than in healthy individuals and significantly (P =0.02) higher in cancer patients with concomitant urothelial dysplasia than in those with normal urothelium. For individuals Lewis-genotyped as homozygous wild-type, Ca 19-9 concentrations in urine were higher, both in cancer patients (P = 0.06) and in healthy individuals (P = 0.004), than in the heterozygous individuals. Furthermore, nonsecretor cancer patients had higher (P <0.01) Ca 19-9 concentrations in urine. Attention is drawn to the possibility of a general genotype interpretation of a result in clinical chemistry.

Download Full-text

Soluble CD138/Syndecan-1 Increases in the Sera of Patients with Moderately Differentiated Bladder Cancer

Urologia Internationalis ◽

10.1159/000364907 ◽

2014 ◽

Vol 94 (4) ◽

pp. 472-478 ◽

Cited By ~ 5

Author(s):

Mohammad Nabi Sanaee ◽

Mahyar Malekzadeh ◽

Abdolaziz Khezri ◽

Abbas Ghaderi ◽

Mehrnoosh Doroudchi

Keyword(s):

Bladder Cancer ◽

Cell Surface ◽

Cancer Patients ◽

Stromal Cells ◽

Elisa Assay ◽

Breast Cancers ◽

Healthy Individuals ◽

Poorly Differentiated ◽

Male Patients ◽

Muscle Invasive

Background: CD138/Syndecan-1 (Sdc-1) is expressed on the tumor and stromal cells of invasive bladder carcinoma. CD138/Sdc-1 shedding from the cell surface is associated with the invasive phenotype in lung and breast cancers. Patients and Methods: Soluble CD138/Sdc-1 was measured in the sera of 86 bladder cancer patients and 57 healthy individuals by a commercial ELISA assay. Results: Soluble Sdc-1 was increased in the sera of patients with bladder cancer (138.42 ± 81.85 vs. 86.48 ± 82.58 ng/ml, p = 0.0003). Patients aged over 70 years had higher levels of CD138/Sdc-1 in their sera (159.7 ± 15.77 vs. 124.5 ± 9.99 ng/ml, p = 0.025), and soluble Sdc-1 levels were higher in the sera of patients with moderately differentiated tumors compared to poorly differentiated ones (170.47 ± 85.06 vs. 101.79 ± 68.24 ng/ml, p = 0.01). The soluble Sdc-1 level was higher in muscle-invasive (154.45 ± 83.60 vs. 89.9 ± 55.02 ng/ml) but not lymphatic-invasive (106.25 ± 52.10 vs. 123.43 ± 63.76 ng/ml) tumors (p = 0.027 and 0.45, respectively). A non-significant trend of soluble Sdc-1 increase in the sera of male patients compared to female patients was observed (145.38 ± 85.47 vs. 110.20 ± 59.04 ng/ml, p = 0.054). Conclusion: The elevated levels of soluble CD138/Sdc-1 in older bladder cancer patients and those with muscular invasion sheds some light on the mechanisms of the disease invasion.

Download Full-text

p53 Mutation in Bladder Cancer Patients in Japan and Inhibition of Growth byin VitroAdenovirus-Mediated Wild-Type p53 Transduction in Bladder Cancer Cells

Molecular Urology ◽

10.1089/109153601300177556 ◽

2001 ◽

Vol 5 (2) ◽

pp. 53-58 ◽

Cited By ~ 6

Author(s):

Akira Irie ◽

Toyoaki Uchida ◽

Hironori Ishida ◽

Kazumasa Matsumoto ◽

Masatsugu Iwamura ◽

...

Keyword(s):

Bladder Cancer ◽

Cancer Cells ◽

Cancer Patients ◽

P53 Mutation ◽

Wild Type ◽

Inhibition Of Growth ◽

Bladder Cancer Cells ◽

Wild Type P53

Download Full-text

Clinical Study of the Serotonin, Melatonin, Estradiol, and Adiponectin Hormones in Women with Breast Cancer in Thi – Qar Governorate -Iraq

International Journal of Pharmaceutical Quality Assurance ◽

10.25258/ijpqa.10.1.25 ◽

2019 ◽

Vol 10 (01) ◽

Author(s):

Hadeel Rashid Faraj1 ◽

Husam Mohammed Kredy

Keyword(s):

Breast Cancer ◽

Cancer Patients ◽

Healthy Subjects ◽

Control Group ◽

Serum Estradiol ◽

Breast Cancer Patients ◽

Healthy Individuals ◽

Common Cause ◽

Serum Serotonin ◽

Apparently Healthy

Objective: Breast cancer is the most widely cancer among women, involving 18% of all female cancers, and worldwide, breast cancer is the fifth most common cause of cancer mortality. The study was designed to determine and compare the levels of Serotonin (ST), Melatonin (MT), Estradiol (E2), and Adiponectin (ADP) Hormones in Breast cancer patients and apparently healthy individuals. Material and Methods: Blood Serotonin (ST), Melatonin (MT), Estradiol(E2), and Adiponectin (ADP) Hormones levels were determined in 85 Breast cancer patients and 55 apparently healthy subjects. Results: The levels of serum Serotonin (ST), Melatonin (MT), and Adiponectin (ADP) Hormones were showing significant decrease in Breast cancer patients as compared to control group. ( P ≤ 0.05 ).While the level of serum Estradiol (E2) was showing significant increase in Breast cancer patients as compared to control group.( P ≤ 0.05 ). Conclusion: In Breast cancer patients, we finding decrease in Serotonin (ST), Melatonin (MT), and Adiponectin (ADP) Hormones. While we finding increase in Estradiol (E2) in Breast cancer patients as compared to control group.

Download Full-text

The prognostic impact of GSTM1/GSTP1 genetic variants in bladder Cancer

BMC Cancer ◽

10.1186/s12885-019-6244-6 ◽

2019 ◽

Vol 19 (1) ◽

Cited By ~ 2

Author(s):

Nada Albarakati ◽

Dareen Khayyat ◽

Asharf Dallol ◽

Jaudah Al-Maghrabi ◽

Taoufik Nedjadi

Keyword(s):

Overall Survival ◽

Bladder Cancer ◽

Protein Expression ◽

Cancer Patients ◽

Genetic Variants ◽

Clinicopathological Parameters ◽

Wild Type ◽

Poor Survival ◽

Her2 Protein ◽

Kaplan Meier

Abstract Background The glutathione S-transferases (GSTs) are a superfamily of phase II detoxifying enzymes that inactivates a wide variety of potential carcinogens through glutathione conjugation. Polymorphic changes in the GST genes have been reported to be associated with increased susceptibility to cancer development and anticancer drug resistance. In this study, we investigated the association between genetic variants in GSTM1 and GSTP1 and patients’ clinicopathological parameters. The prognostic values of such associations were evaluated among bladder cancer patients. Methods Genotyping of GSTM1 and GSTP1 in bladder cancer patients was assessed using polymerase chain reaction followed by DNA sequencing. Overall survival was estimated using the Kaplan-Meier method and multiple logistic regression and correlation analysis were performed. Results The GSTM1 null genotype was significantly associated with poor overall survival compared with the wild-type GSTM1 genotype. There was a trend towards better overall survival in patients with wild-type GSTP1 allele (AA) compared with GSTP1 (AG/GG) genotype. Interestingly, Kaplan-meier survival curve for GSTM1 null patients adjusted for sub-cohort with amplified HER2 gene showed poor survival compared with the GSTM1 null/ non-amplified HER2 gene. Also the same population when adjusted with HER2 protein expression, data showed poor survival for patients harboring GSTM1 null/high HER2 protein expression compared with low protein expression. Conclusion This study focuses on the impact of GSTM1 null genotype on bladder cancer patients’ outcome. Further investigations are required to delineate the underlying mechanisms of combined GSTM−/− and HER2 status in bladder cancer.

Download Full-text

The influence of haematuria on the utility of the BTA stat test in the diagnosis of bladder cancer: a prospective study

10.21203/rs.3.rs-64771/v3 ◽

2021 ◽

Author(s):

Xiong Xiong ◽

Wei He ◽

Bin Xiong ◽

Feng Yao

Keyword(s):

Bladder Cancer ◽

Cancer Patients ◽

Bladder Tumour ◽

Healthy Individuals ◽

Clinical Cohort ◽

Renal Hamartoma ◽

A Prospective Study ◽

Urologic Cancers ◽

Urinary Bladder Tumour ◽

Bta Stat

Abstract Background The urinary bladder tumour antigen (BTA) stat test has already been used for the diagnosis and monitoring of bladder cancer (BC). However, more evidence is needed regarding its efficacy and utility in the clinic. In this study, we investigated the influence of haematuria on the performance of the BTA stat test in a clinical cohort.Methods Urine samples from 836 subjects, including 50 healthy volunteers, 553 patients with benign urologic disorders, 124 patients with histologically proven BC, and 109 patients with other histologically proven urologic cancers, were analysed by the BTA stat test and urinalysis. We detected the sensitivity and specificity of the BTA stat test in each group and analysed the effect of haematuria on the specificity.Results Our data show that 58.06% of patients in the BC group had haematuria. Haematuria with benign prostatic hyperplasia (BPH), renal hamartoma (RH) and urolithiasis were identified in 39.01%, 42.86% and 66.49% of patients with benign urologic disorders, respectively. Haematuria was identified in 48.72% of prostatic cancer patients and 67.74% of renal cancer patients. The overall sensitivity of the BTA stat test was 90.32%. The sensitivity was 97.22% in BC patients with haematuria and 80.77% in BC patients without haematuria. The overall specificity in healthy individuals, patients with benign urologic disorders and patients with other urologic cancers was 50.84%. In all patients with haematuria, the specificity of the BTA stat test was 15.82%, while the specificity was 72.6% in patients without haematuria.Conclusions Haematuria has a significant influence on the BTA stat test. The performance of the BTA stat test can be increased if patients with known or obvious haematuria conditions are excluded from the test.

Download Full-text

The influence of haematuria on the utility of the BTA stat test in the diagnosis of bladder cancer: a prospective study

10.21203/rs.3.rs-64771/v2 ◽

2020 ◽

Author(s):

Xiong Xiong ◽

Wei He ◽

Bin Xiong ◽

Feng Yao

Keyword(s):

Bladder Cancer ◽

Cancer Patients ◽

Bladder Tumour ◽

Healthy Individuals ◽

Clinical Cohort ◽

Renal Hamartoma ◽

A Prospective Study ◽

Urologic Cancers ◽

Urinary Bladder Tumour ◽

Bta Stat

Abstract Background: The urinary bladder tumour antigen (BTA) stat test has already been used for the diagnosis and monitoring of bladder cancer (BC). However, more evidence is needed regarding its efficacy and utility in the clinic. In this study, we investigated the influence of haematuria on the performance of the BTA stat test in a clinical cohort. Methods: Urine samples from 836 subjects, including 50 healthy volunteers, 553 patients with benign urologic disorders, 124 patients with histologically proven BC, and 109 patients with other histologically proven urologic cancers, were analysed by the BTA stat test and urinalysis. We detected the sensitivity and specificity of the BTA stat test in each group, and analysed the effect of haematuria on the specificity. Results: Our data showed that 58.06% of patients had haematuria in the BC group. Haematuria with benign prostatic hyperplasia (BPH), renal hamartoma (RH) and urolithiasis were identified in 39.01%, 42.86% and 66.49% of patients with benign urologic disorders, respectively. Haematuria was identified in 48.72% of prostatic cancer patients and 67.74% of renal cancer patients. The overall sensitivity of the BTA stat test was 90.32%. The sensitivity was 97.22% in BC patients with haematuria and 80.77% in BC patients without haematuria. The overall specificity in healthy individuals, patients with benign urologic disorders and other urologic cancers was 50.84%. In all patients with haematuria, the specificity of the BTA stat test was 15.82%, while it was 72.6% in patients without haematuria. Conclusions: Haematuria has a significant influence on the BTA stat test. Thus, this test should not be used for the diagnosis of bladder cancer in patients with haematuria.

Download Full-text

Fluorescence in situ hybridization detects frequent chromosome 9 deletions and aneuploidy in histologically normal urothelium of bladder cancer patients

Oncology Reports ◽

10.3892/or.11.4.745 ◽

2004 ◽

Cited By ~ 1

Author(s):

Ellen Obermann ◽

Stefanie Meyer ◽

Dorothea Hellge ◽

Dirk Zaak ◽

Thomas Filbeck ◽

...

Keyword(s):

Bladder Cancer ◽

In Situ Hybridization ◽

Fluorescence In Situ Hybridization ◽

Cancer Patients ◽

Chromosome 9 ◽

Normal Urothelium

Download Full-text

Interference From Haematuria Renders the Urinary BTA Test Not Specific Enough for Diagnosing Bladder Cancer: Evidence From Clinical Practice

10.21203/rs.3.rs-64771/v1 ◽

2020 ◽

Author(s):

Xiong Xiong ◽

Wei He ◽

Bin Xiong ◽

Feng Yao

Keyword(s):

Bladder Cancer ◽

Cancer Patients ◽

Bladder Tumour ◽

Prostatic Hyperplasia ◽

Healthy Individuals ◽

Clinical Cohort ◽

Renal Hamartoma ◽

Urologic Cancers ◽

Urinary Bladder Tumour ◽

Bta Stat

Abstract Background The urinary bladder tumour antigen (BTA) stat test has already been used for the diagnosis and monitoring of bladder cancer (BC). However, more evidence is needed regarding its efficacy and utility in the clinic. In this study, we investigated the influence of haematuria on the performance of the BTA stat test in a clinical cohort.Methods Urine samples from 836 subjects, including 50 healthy volunteers, 553 patients with benign urologic disorders, 124 patients with histologically proven BC, and 109 patients with other histologically proven urologic cancers, were analysed by the BTA stat test and urinalysis. We detected the sensitivity and specificity of the BTA stat test in each group, and analysed the effect of haematuria on the specificity.Results Our data showed that 58.06% of patients had haematuria in the BC group. Haematuria with benign prostatic hyperplasia (BPH), renal hamartoma (RH) and urolithiasis were identified in 39.01%, 42.86% and 66.49% of patients with benign urologic disorders, respectively. Haematuria was identified in 48.72% of prostatic cancer patients and 67.74% of renal cancer patients. The overall sensitivity of the BTA stat test was 90.32%. The sensitivity was 97.22% in BC patients with haematuria and 80.77% in BC patients without haematuria. The overall specificity in healthy individuals, patients with benign urologic disorders and other urologic cancers was 50.84%. In all patients with haematuria, the specificity of the BTA stat test was 15.82%, while it was 72.6% in patients without haematuria.Conclusions Haematuria has a significant influence on the BTA stat test. Our study suggested that the BTA stat test is not an ideal diagnostic tool for BC.

Download Full-text